Adam Vilmar

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

Adam Vilmar, Eric Santoni‐Rugiu, Jens Benn Sørensen · Annals of Oncology · 2010 · 68 citations

Medicine, Oncology, Pathology +10

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC

Adam Vilmar, Jesús García‐Foncillas, Marisol González-Huarriz et al. · Lung Cancer · 2011 · 54 citations

Medicine, Molecular Biology, Oncology +10

<scp>Real‐world</scp> experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The <scp>SCHOLAR</scp>‐2 retrospective chart review study

Martin Dreyling, Lucie Obéric, Eva Giné et al. · British Journal of Haematology · 2022 · 44 citations · Full text

Medicine, Hematology, Oncology +15

Class III β-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial

Adam Vilmar, Eric Santoni‐Rugiu, Jens Benn Sørensen · Clinical Cancer Research · 2011 · 43 citations

Medicine, Oncology, Pharmacology +17

ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial

Adam Vilmar, Eric Santoni‐Rugiu, Jens Benn Sørensen · European Journal of Cancer · 2010 · 26 citations

Pharmacy, Oncology, Cancer Drug Toxicity Management +11